^
    Back
    Association details:
    Biomarker:LMNA-NTRK1 fusion
    Cancer:Breast Cancer
    Drug:Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2020
    Title:

    Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer

    Published date:
    05/15/2020
    Excerpt:
    Two patients with acquired LMNA-NTRK1 fusions and metastatic disease received larotrectinib and demonstrated clinical benefit.
    DOI:
    10.1158/1538-7445.AM2020-5280
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients

    Published date:
    04/30/2020
    Excerpt:
    Two patients with acquired LMNA-NTRK1 fusions and metastatic disease received larotrectinib and demonstrated clinical benefit.
    DOI:
    10.1016/j.annonc.2020.04.008
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    AACR-II 2020
    Title:

    Abstract 5280: Kinase fusions drive endocrine resistance in estrogen receptor-positive breast cancer

    Published date:
    05/15/2020
    Excerpt:
    ...fulvestrant and the Trk inhibitor larotrectinib completely blocked the growth of LMNA-NTRK+ breast cancer cells.
    Secondary therapy:
    fulvestrant
    DOI:
    10.1158/1538-7445.AM2020-5280